According to findings from the REGARDS trial, peripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients. These findings suggest that cytopenia may be an early marker of severe disease, according to the study authors. The report was shared at the 2021 ASH Annual Meeting. REGARDS included 30,239 U.S. individuals who were followed with a semiannual phone interview through 2018 for cytopenia and cancer mortality. Investigators calculated the risk of cytopenia-related cancer mortality in three Cox proportional hazards models: ...
Advertisement
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
“The results of ZUMA-7 herald a paradigm shift in how we treat large B-cell lymphoma."
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
This lack of benefit was seen in the entire study population.
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
Advertisement
